Semaglutide is a GLP-1 receptor agonist licensed for type 2 diabetes and weight management in the UK No direct mechanism exists linking semaglutide to reduced oestrogen production at the ovarian level Weight loss decreases adipose tissue containing aromatase enzyme, potentially reducing peripheral oestrogen conversion, particularly in postmenopausal women Semaglutide does not affect oral contraceptive efficacy and should be discontinued at least two months before planned pregnancy Women experiencing menstrual irregularities or severe menopausal symptoms during treatment should seek medical advice for appropriate investigation Table of Contents Understanding Ozempic and Hormonal Effects Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses under the brand name Wegovy, for weight management in adults with obesity or overweight with weight-related comorbidities

Liver Regeneration, Growth Factors, and Amphiregulin
Doal takviyeler tek bana yeterli olmasa da diet and exercise ile birlikte salkl yaam alkanlklarn destekleyebilir
Sack RL, Brandes RW, Kendall AR, Lewy AJ
doi: 10.3390/cancers14061531 68 ThanasCZirosPGChartoumpekisDVRenaudCOSykiotisGP
"Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning." J Neurosci 19(10): 3952-61